Drug Profile
Milademetan - Daiichi Sankyo
Alternative Names: DS-3032; DS3032b; RAIN-32Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Developer Daiichi Sankyo Inc; National Cancer Center Hospital East; Rain Oncology; University of Texas M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Cyclohexanes; Halogenated hydrocarbons; Indoles; Pyrans; Pyrrolidines; Small molecules; Spiro compounds
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liposarcoma
- Phase II Sarcoma; Solid tumours
- Phase I/II Acute myeloid leukaemia
- Phase I Unspecified
- Preclinical Malignant-mesothelioma
- No development reported Lymphoma; Multiple myeloma; Myelodysplastic syndromes
Most Recent Events
- 21 Dec 2023 Rain Oncology in collaboration with Institut Curie terminates the phase II DEMETER trial for HER2-negative Breast cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in France (NCT05932667)
- 20 Oct 2023 Updated efficacy and adverse events data from a phase III MANTRA trial in Liposarcoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 15 Oct 2023 Rain Oncology terminates a phase II MANTRA-2 trial for Solid tumours (Late-stage disease, Second-line therapy or greater, In adults, In the elderly, Metastatic disease) in USA (PO) due to sponsor's decision (NCT05012397)